{"entity":{"edinet_code":"E21183","sec_code":"4578","name_ja":"大塚ホールディングス株式会社","name_en":"Otsuka Holdings Co., Ltd.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100XUA7","filer_name":"大塚ホールディングス株式会社","filer_name_en":"Otsuka Holdings Co., Ltd.","period_end":"2025-12-31","filed_date":"2026-03-26","sha256":"903a9ae97751e3df0c9e08581596c070ea66c6e0b0df40e815c66edfdb8a6999","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"holdco_consolidated","share_scope":"both","trust_included":"unknown","as_of":"2025-12-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"Every disclosing entity in the filing, summed — the reporting company plus each group holder it names.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"largest","held_name_raw":"第一三共㈱","held_name_en":"DAIICHI SANKYO COMPANY, LIMITED","held_sec_code":"4568","match_status":"matched","shares":6406200,"book_value_yen":21447000000,"prior_shares":6406200,"prior_book_value_yen":27879000000,"purpose_ja":"当社グループ会社において受託事業の取引があり、事業上の関係の維持・強化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.34933498089093973,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7070181615352056,"pct_of_holder_assets":0.5109394453256438,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱阿波銀行","held_name_en":"The Awa Bank，Ltd.","held_sec_code":"8388","match_status":"matched","shares":932200,"book_value_yen":4087000000,"prior_shares":932200,"prior_book_value_yen":2537000000,"purpose_ja":"主要金融機関との安定的な金融・資金取引の協力関係維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤及び財務活動の円滑化に寄与する関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":2.3484539302971217,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.13473134826289854,"pct_of_holder_assets":0.09736604247894373,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"東邦ホールディングス㈱","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":789800,"book_value_yen":3686000000,"prior_shares":789800,"prior_book_value_yen":3372000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":1.2211027457619246,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.12151205032959238,"pct_of_holder_assets":0.08781287804682814,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":1160494,"book_value_yen":3214000000,"prior_shares":1160494,"prior_book_value_yen":2762000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.5669280404898827,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10595217844799508,"pct_of_holder_assets":0.07656825557311601,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"Dong-A Socio Holdings Co., Ltd.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":255948,"book_value_yen":3077000000,"prior_shares":248494,"prior_book_value_yen":2935000000,"purpose_ja":"韓国におけるニュートラシューティカルズ関連製品の製造販売を担う東亜大塚㈱の株主であるDong-A Socio Holdings Co., Ltd. との協働関係を通じて、同国における大塚製薬㈱グループ製品の安定的な供給体制の維持及び事業基盤の強化を図っております。これら事業運営上の重要な関係を継続・発展させることを目的として、同社株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。株式配当により株式が増加しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.10143585970270096,"pct_of_holder_assets":0.07330445625341567,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"Dong-A ST Co., Ltd.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":446686,"book_value_yen":2572000000,"prior_shares":437928,"prior_book_value_yen":2770000000,"purpose_ja":"韓国におけるニュートラシューティカルズ関連事業の製造販売を担う東亜大塚㈱の株主であるDong-A Socio Holdings グループと長年にわたり協働関係を構築してきておりますが、同グループの医薬品分野における中核会社である Dong-A ST Co., Ltd. との関係維持を目的として、同社株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。株式配当により株式が増加しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.08478811542260216,"pct_of_holder_assets":0.06127366314065164,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":1176500,"book_value_yen":2555000000,"prior_shares":1176500,"prior_book_value_yen":1922000000,"purpose_ja":"子会社における事業上の関係の維持・強化のため、事業基盤の安定化に資する協力関係の構築を図るため、保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.2459723979873123,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0842276963082226,"pct_of_holder_assets":0.06086866614477642,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"Arcus Biosciences, Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":585569,"book_value_yen":2184000000,"prior_shares":585569,"prior_book_value_yen":1379000000,"purpose_ja":"同社は、大鵬薬品工業㈱が日本及びアジアにおける独占的開発・販売権を取得している複数のがん免疫領域パイプラインを保有する重要な提携先であり、当社のがん領域研究開発における中核的パートナーです。これらの革新的治療薬の開発を安定的かつ長期的に推進するため、同社との関係強化及び共同開発体制の強化を目的として株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.07199737328264508,"pct_of_holder_assets":0.05203020229361711,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"雪印メグミルク㈱","held_name_en":"MEGMILK SNOW BRAND Co.,Ltd.","held_sec_code":"2270","match_status":"matched","shares":620000,"book_value_yen":2005000000,"prior_shares":620000,"prior_book_value_yen":1712000000,"purpose_ja":"当社グループは、同社グループと委託製造及び販売に関する協働を継続しておりますが、これらの取引関係は企業価値の向上に資すると判断しており、関係の維持・強化を目的として継続保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":1.0204055601898974,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06609648966653085,"pct_of_holder_assets":0.047765822160577974,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"松竹㈱","held_name_en":"Shochiku Co., Ltd.","held_sec_code":"9601","match_status":"matched","shares":142400,"book_value_yen":1690000000,"prior_shares":142400,"prior_book_value_yen":1563000000,"purpose_ja":"歌舞伎座オフィシャル・パートナーとして協賛・支援を行い、広報活動等を通じて互いに企業価値を高めることを目的として保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":1.030215034961114,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.05571225313538011,"pct_of_holder_assets":0.04026146606053704,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東洋製罐グループホールディングス㈱","held_name_en":"Toyo Seikan Group Holdings, Ltd.","held_sec_code":"5901","match_status":"matched","shares":400000,"book_value_yen":1530000000,"prior_shares":400000,"prior_book_value_yen":962000000,"purpose_ja":"大塚グループとして、主に包装容器の仕入等を行っており、関係の維持・強化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.26518452911866014,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.050437720294160694,"pct_of_holder_assets":0.036449729628770224,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":228860,"book_value_yen":1403000000,"prior_shares":228860,"prior_book_value_yen":1084000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.33836057368069833,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04625105985144278,"pct_of_holder_assets":0.03342416383605531,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"Jeil Pharma Holdings Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":1497050,"book_value_yen":1315000000,"prior_shares":1497050,"prior_book_value_yen":1259000000,"purpose_ja":"韓国における医薬品事業を展開する韓国大塚製薬㈱が、大塚製薬㈱とJeil Pharma Holdingsグループとの合弁により設立された経緯を通じて、同グループとの間で長年にわたり協働関係を築いております。これら事業上の関係性の維持が韓国における医薬品事業の安定的な推進に重要であることから、同社の株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0433500667887721,"pct_of_holder_assets":0.031327708798583556,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アルフレッサ ホールディングス㈱","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":399444,"book_value_yen":971000000,"prior_shares":399444,"prior_book_value_yen":864000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.21923104154009032,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.032009821180150354,"pct_of_holder_assets":0.023132475470284894,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱りそなホールディングス","held_name_en":"Resona Holdings, Inc.","held_sec_code":"8308","match_status":"matched","shares":491100,"book_value_yen":733000000,"prior_shares":491100,"prior_book_value_yen":562000000,"purpose_ja":"主要金融機関との安定的な金融・資金取引の協力関係維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤及び財務活動の円滑化に寄与する関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.02171048310318192,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.024163953578836463,"pct_of_holder_assets":0.017462517528031747,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"GlycoNex Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":3036000,"book_value_yen":390000000,"prior_shares":3036000,"prior_book_value_yen":366000000,"purpose_ja":"過去の共同研究開発の協力を踏まえ、医療・創薬分野における技術動向や研究開発情報の把握を目的として保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.012856673800472335,"pct_of_holder_assets":0.009291107552431626,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":423204,"book_value_yen":385000000,"prior_shares":419878,"prior_book_value_yen":370000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。持株会により株式が増加しております。","reciprocal":"有","pct_outstanding":2.05876572518267,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.012691844649184228,"pct_of_holder_assets":0.009171990788938912,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":268500,"book_value_yen":367000000,"prior_shares":268500,"prior_book_value_yen":335000000,"purpose_ja":"医薬品販売等に係る事業上の関係の維持・強化を目的として保有しています。これにより、大塚製薬㈱の事業基盤の安定化に資する協力関係の構築を図っています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.5538700395213606,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.012098459704547043,"pct_of_holder_assets":0.008743170440365145,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"伊藤忠食品㈱","held_name_en":"ITOCHU-SHOKUHIN Co., Ltd.","held_sec_code":null,"match_status":"matched","shares":20000,"book_value_yen":224000000,"prior_shares":20000,"prior_book_value_yen":143000000,"purpose_ja":"ニュートラシューティカルズ関連製品の流通機能の維持・強化や市場動向の把握を目的として保有しています。これにより、大塚製薬㈱製品の安定供給体制の確保や、流通事業における協力関係の深化に資するものと判断しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.1576416804603137,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0073843459777071865,"pct_of_holder_assets":0.005336431004473549,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"Werewolf Therapeutics, Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":2068909,"book_value_yen":204000000,"prior_shares":2068909,"prior_book_value_yen":484000000,"purpose_ja":"同社は、腫瘍局所でのみ活性化する独自のPREDATOR® 技術を活用した次世代型サイトカイン治療の研究開発を行う企業であり、コーポレートベンチャーキャピタルである大鵬ベンチャーズ LLCを通じて戦略的に出資を行っている企業です。がん免疫領域における革新的モダリティの探索及び将来的な協業可能性の創出を目的として株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.006725029372554759,"pct_of_holder_assets":0.004859963950502697,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"大木ヘルスケアホールディングス㈱","held_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","held_sec_code":"3417","match_status":"matched","shares":99125,"book_value_yen":140000000,"prior_shares":99125,"prior_book_value_yen":80000000,"purpose_ja":"同社が有する全国規模のドラッグストア向け販売網と製品供給機能を通じて、ニュートラシューティカルズ関連製品の安定的な販売チャネルを確保しています。これらの協働は、大塚製薬㈱製品の市場浸透及び流通効率の向上に寄与し、大塚製薬㈱グループの事業基盤及び企業価値の向上に資することから、同社株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.7268294471330107,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.004615216236066992,"pct_of_holder_assets":0.003335269377795968,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"エイチ・ツー・オーリテイリング㈱","held_name_en":"H2O RETAILING CORPORATION","held_sec_code":"8242","match_status":"matched","shares":51289,"book_value_yen":105000000,"prior_shares":56084,"prior_book_value_yen":129000000,"purpose_ja":"定期的に個別銘柄について検討した結果、一部売却しております。残存する株式は持株会によるものです。","reciprocal":"無","pct_outstanding":0.04459777466243287,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.003461412177050244,"pct_of_holder_assets":0.002501452033346976,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"イオン㈱","held_name_en":"AEON CO.,LTD.","held_sec_code":"8267","match_status":"matched","shares":41371,"book_value_yen":102000000,"prior_shares":20362,"prior_book_value_yen":75000000,"purpose_ja":"定期的に個別銘柄について検討した結果、一部売却しております。残存する株式は持株会によるものですが、持株会と株式分割により株式が増加しております。","reciprocal":"無","pct_outstanding":0.0014958229939237562,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.0033625146862773796,"pct_of_holder_assets":0.0024299819752513483,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":["share split"],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"西日本旅客鉄道㈱","held_name_en":"West Japan Railway Company","held_sec_code":"9021","match_status":"matched","shares":30000,"book_value_yen":93000000,"prior_shares":30000,"prior_book_value_yen":83000000,"purpose_ja":"同社グループが展開する鉄道関連小売業態や自動販売機網を通じて、ニュートラシューティカルズ関連製品の販売機会が提供されており、大塚製薬㈱製品の消費者接点の確保及び市場浸透に寄与しています。これらの事業上の関係の維持は、大塚製薬㈱グループの販売基盤の安定化に資すると判断しており、同社株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.006600339125424264,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0030658222139587875,"pct_of_holder_assets":0.0022155718009644644,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱セブン＆アイ・ホールディングス","held_name_en":"Seven & i Holdings Co., Ltd.","held_sec_code":"3382","match_status":"matched","shares":34937,"book_value_yen":78000000,"prior_shares":87749,"prior_book_value_yen":218000000,"purpose_ja":"定期的に個別銘柄について検討した結果、一部売却しております。残存する株式は持株会によるものです。","reciprocal":"無","pct_outstanding":0.0015093059581639267,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.0025713347600944667,"pct_of_holder_assets":0.0018582215104863253,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"NextCure, Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":32481,"book_value_yen":72000000,"prior_shares":389773,"prior_book_value_yen":47000000,"purpose_ja":"同社は、独自のFIND IO™プラットフォームを活用して、革新的な医薬品の開発に注力しているバイオ医薬品企業であり、コーポレートベンチャーキャピタルである大鵬ベンチャーズ LLC を通じて戦略的に出資を行っている企業です。革新的モダリティの探索及び将来的な協業可能性の創出を目的として株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。定期的に個別銘柄について検討した結果、部分売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0023735397785487385,"pct_of_holder_assets":0.0017152813942950694,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":26000,"book_value_yen":56000000,"prior_shares":26000,"prior_book_value_yen":42000000,"purpose_ja":"医療関連事業の運営に資する業界動向や事業理解の深化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.005435854099167123,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0018460864944267966,"pct_of_holder_assets":0.0013341077511183873,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"セントラルフォレストグループ㈱","held_name_en":"Central Forest Group, Inc.","held_sec_code":"7675","match_status":"matched","shares":20000,"book_value_yen":55000000,"prior_shares":20000,"prior_book_value_yen":47000000,"purpose_ja":"ニュートラシューティカルズ関連製品の流通機能の維持・強化や市場動向の把握を目的として保有しています。これにより、大塚製薬㈱製品の安定供給体制の確保や、流通事業における協力関係の深化に資するものと判断しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.2445391653315847,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.0018131206641691753,"pct_of_holder_assets":0.0013102843984198447,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ヤマエグループホールディングス㈱","held_name_en":"YAMAE GROUP HOLDINGS CO.,LTD.","held_sec_code":"7130","match_status":"matched","shares":18789,"book_value_yen":47000000,"prior_shares":18539,"prior_book_value_yen":36000000,"purpose_ja":"ニュートラシューティカルズ関連製品の流通機能の維持・強化や市場動向の把握を目的として保有しています。これにより、大塚製薬㈱製品の安定供給体制の確保や、流通事業における協力関係の深化に資するものと判断しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。持株会により株式が増加しております。","reciprocal":"無","pct_outstanding":0.06766945239065597,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0015493940221082043,"pct_of_holder_assets":0.0011196975768315036,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ＡＮＡホールディングス㈱","held_name_en":"ANA HOLDINGS INC.","held_sec_code":"9202","match_status":"matched","shares":10000,"book_value_yen":29000000,"prior_shares":10000,"prior_book_value_yen":28000000,"purpose_ja":"販売等取引関係の維持・強化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.002174102752848688,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":2,"pct_of_holder_equity":0.0009560090774710197,"pct_of_holder_assets":0.0006908772282577363,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アルテック㈱","held_name_en":"ALTECH CO., LTD.","held_sec_code":"9972","match_status":"matched","shares":103000,"book_value_yen":29000000,"prior_shares":103000,"prior_book_value_yen":21000000,"purpose_ja":"飲料容器関連資材の安定調達及び供給体制の維持を目的として保有しています。同社とは、大塚製薬㈱製品の製造に必要な資材の安定供給を確保するうえで重要な取引関係を構築しており、持続的な事業運営に資するものと判断しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.7480354990050402,"pct_unavailable":null,"pct_basis_period_end":"2025-11-30","pct_share_classes":1,"pct_of_holder_equity":0.0009560090774710197,"pct_of_holder_assets":0.0006908772282577363,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"東日本旅客鉄道㈱","held_name_en":"East Japan Railway Company","held_sec_code":"9020","match_status":"matched","shares":6000,"book_value_yen":24000000,"prior_shares":6000,"prior_book_value_yen":16000000,"purpose_ja":"同社グループが展開する鉄道関連小売業態や自動販売機網を通じて、ニュートラシューティカルズ関連製品の販売機会が提供されており、大塚製薬㈱製品の消費者接点の確保及び市場浸透に寄与しています。これらの事業上の関係の維持は、大塚製薬㈱グループの販売基盤の安定化に資すると判断しており、同社株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.0005299017367882691,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0007911799261829128,"pct_of_holder_assets":0.0005717604647650232,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱マルイチ産商","held_name_en":"MARUICHI Co.,Ltd.","held_sec_code":"8228","match_status":"matched","shares":19230,"book_value_yen":22000000,"prior_shares":18427,"prior_book_value_yen":20000000,"purpose_ja":"ニュートラシューティカルズ関連製品の流通機能の維持・強化や市場動向の把握を目的として保有しています。これにより、大塚製薬㈱製品の安定供給体制の確保や、流通事業における協力関係の深化に資するものと判断しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。持株会により株式が増加しております。","reciprocal":"無","pct_outstanding":0.09707904647476348,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0007252482656676701,"pct_of_holder_assets":0.0005241137593679379,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アシードホールディングス㈱","held_name_en":"ASEED HOLDINGS CO.,LTD.","held_sec_code":"9959","match_status":"matched","shares":24000,"book_value_yen":18000000,"prior_shares":24000,"prior_book_value_yen":15000000,"purpose_ja":"同社による自動販売機オペレーションを通じて大塚専用機の維持管理及び新規ロケーション開拓の支援を受けており、ニュートラシューティカルズ関連製品の販売チャネルの安定運営に寄与しています。これらの協働は事業基盤の強化と企業価値向上に資することから、同社株式を保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.1945517721720927,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0005933849446371846,"pct_of_holder_assets":0.00042882034857376735,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"カメイ㈱","held_name_en":"KAMEI CORPORATION","held_sec_code":"8037","match_status":"matched","shares":3000,"book_value_yen":9000000,"prior_shares":3000,"prior_book_value_yen":5000000,"purpose_ja":"ニュートラシューティカルズ関連製品の流通機能の維持・強化や市場動向の把握を目的として保有しています。これにより、大塚製薬㈱製品の安定供給体制の確保や、流通事業における協力関係の深化に資するものと判断しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.009804123738630035,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0002966924723185923,"pct_of_holder_assets":0.00021441017428688367,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"セガサミーホールディングス㈱","held_name_en":"SEGA SAMMY HOLDINGS INC.","held_sec_code":"6460","match_status":"matched","shares":1300,"book_value_yen":3000000,"prior_shares":1300,"prior_book_value_yen":3000000,"purpose_ja":"販売等取引関係の維持・強化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"無","pct_outstanding":0.0006352480288791181,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":9.88974907728641e-05,"pct_of_holder_assets":7.14700580956279e-05,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アルビス㈱","held_name_en":"ALBIS Co.,Ltd.","held_sec_code":"7475","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":2000,"prior_book_value_yen":5000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ベルク","held_name_en":"Belc CO., LTD.","held_sec_code":"9974","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":2000,"prior_book_value_yen":13000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ヤマナカ","held_name_en":"YAMANAKA CO.,LTD.","held_sec_code":"8190","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":8000,"prior_book_value_yen":4000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-20","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱ヤマザワ","held_name_en":"YAMAZAWA CO.,LTD.","held_sec_code":"9993","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1452,"prior_book_value_yen":1000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ユナイテッド・スーパーマーケット・ホールディングス㈱","held_name_en":"United Super Markets Holdings Inc.","held_sec_code":"3222","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":2269,"prior_book_value_yen":1000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱オークワ","held_name_en":"ＯＫＵＷＡ ＣＯ., ＬＴＤ.","held_sec_code":"8217","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":10000,"prior_book_value_yen":8000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-20","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"ウエルシアホールディングス㈱","held_name_en":"WELCIA HOLDINGS CO., LTD.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":3200,"prior_book_value_yen":6000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱エコス","held_name_en":"Eco's Co.,Ltd.","held_sec_code":"7520","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":1000,"prior_book_value_yen":2000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"三菱食品㈱","held_name_en":"Mitsubishi Shokuhin Co., Ltd.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":103400,"prior_book_value_yen":519000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"三菱ケミカルグループ㈱","held_name_en":"Mitsubishi Chemical Group Corporation","held_sec_code":"4188","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":12500,"prior_book_value_yen":9000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"アクシアル リテイリング㈱","held_name_en":"Axial Retailing Inc.","held_sec_code":"8255","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":9600,"prior_book_value_yen":8000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱バローホールディングス","held_name_en":"VALOR HOLDINGS CO.,LTD.","held_sec_code":"9956","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":7200,"prior_book_value_yen":15000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"largest","held_name_raw":"㈱リテールパートナーズ","held_name_en":"RETAIL PARTNERS CO., LTD.","held_sec_code":"8167","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":6700,"prior_book_value_yen":8000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"second_largest","held_name_raw":"ORIC Pharmaceuticals, Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":null,"book_value_yen":null,"prior_shares":135316,"prior_book_value_yen":172000000,"purpose_ja":"定期的に個別銘柄について検討した結果、売却しております。","reciprocal":"－","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":null,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社阿波銀行","holder_name_en":"The Awa Bank，Ltd.","holder_sec_code":"8388","doc_id":"S100YAMP","period_end":"2026-03-31","holder_table":"reporting","shares":10970520,"book_value_yen":120785000000,"prior_shares":10970520,"prior_book_value_yen":85054000000,"purpose_ja":"保有目的は「イ　保有方針及び保有の合理性を検証する方法並びに個別銘柄の保有の適否に関する取締役会等における検証の内容」に記載しております。","reciprocal":"無(注)３","pct_outstanding":2.07723298536508,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":30.22519062001867,"pct_of_holder_assets":2.895141167644218,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":399617000000,"holder_total_assets_yen":4171990000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社　りそなホールディングス","holder_name_en":"Resona Holdings, Inc.","holder_sec_code":"8308","doc_id":"S100YDP3","period_end":"2026-03-31","holder_table":"largest","shares":5568520,"book_value_yen":61309000000,"prior_shares":5568520,"prior_book_value_yen":43172000000,"purpose_ja":"事業上の関係を総合的に勘案し、中長期的かつ安定的な取引関係の構築を図るため。","reciprocal":"無","pct_outstanding":1.0543815082297974,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":2.0936270537498256,"pct_of_holder_assets":0.08035477572565176,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":2928363000000,"holder_total_assets_yen":76297892000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":5316000,"book_value_yen":58529000000,"prior_shares":5316000,"prior_book_value_yen":41214000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":1.006567651323799,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":7.35844525829175,"pct_of_holder_assets":3.0452101506658162,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社スズケン","holder_name_en":"SUZUKEN CO.,LTD.","holder_sec_code":"9987","doc_id":"S100YFRU","period_end":"2026-03-31","holder_table":"reporting","shares":3292000,"book_value_yen":36244000000,"prior_shares":3292000,"prior_book_value_yen":25522000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております","reciprocal":"無(注)２","pct_outstanding":0.6233297043186506,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":8.712248685134083,"pct_of_holder_assets":3.1359288991024137,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"second_largest","shares":1464000,"book_value_yen":16118000000,"prior_shares":1464000,"prior_book_value_yen":11305000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注３)","pct_outstanding":0.2772037324187438,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":13.577969285720304,"pct_of_holder_assets":5.027950388061192,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":1400000,"book_value_yen":15414000000,"prior_shares":2000000,"prior_book_value_yen":15506000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.26508553646601185,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":5.6760936809544855,"pct_of_holder_assets":2.0807769097749538,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":1264000,"book_value_yen":13916000000,"prior_shares":1264000,"prior_book_value_yen":9799000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"無(注３)","pct_outstanding":0.2393343700664564,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":11.722981795513324,"pct_of_holder_assets":4.3410446457537875,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"second_largest","shares":1200000,"book_value_yen":13212000000,"prior_shares":1600000,"prior_book_value_yen":12404000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"無(注)４","pct_outstanding":0.2272161741137244,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":2.6012841034607,"pct_of_holder_assets":0.8766993847444221,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"東洋製罐グループホールディングス株式会社","holder_name_en":"Toyo Seikan Group Holdings, Ltd.","holder_sec_code":"5901","doc_id":"S100YGR9","period_end":"2026-03-31","holder_table":"reporting","shares":1000000,"book_value_yen":11010000000,"prior_shares":1000000,"prior_book_value_yen":7753000000,"purpose_ja":"主に包装容器事業において製品の販売等を行っており、取引関係の維持・強化を目的として保有している。","reciprocal":"有","pct_outstanding":0.18934681176143703,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":1.5132086207536357,"pct_of_holder_assets":0.8874079948931726,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":727593000000,"holder_total_assets_yen":1240692000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"雪印メグミルク株式会社","holder_name_en":"MEGMILK SNOW BRAND Co.,Ltd.","holder_sec_code":"2270","doc_id":"S100YC5I","period_end":"2026-03-31","holder_table":"reporting","shares":1000000,"book_value_yen":11010000000,"prior_shares":1000000,"prior_book_value_yen":7753000000,"purpose_ja":"同社グループとは、赤ちゃんとお母さんをはじめとした家族の健康といきいきした暮らしをサポートするために、様々な協業を継続的に行っております。具体的には両社の強みを活かした「ビーンスターク ポカリスエット」などの販売、液体ミルク「すこやかM1」の委託製造、「ビーンスターク」ブランドの商標使用などです。当社グループの事業拡大、企業価値向上を目的として、関係強化を図るため、継続して保有しています。","reciprocal":"有","pct_outstanding":0.18934681176143703,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":4.573379690206488,"pct_of_holder_assets":2.5795417271917906,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":240741000000,"holder_total_assets_yen":426820000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":872000,"book_value_yen":9600000000,"prior_shares":872000,"prior_book_value_yen":6760000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"無(注)３","pct_outstanding":0.16511041985597308,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":1.8901246891630883,"pct_of_holder_assets":0.6370204430477181,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"大木ヘルスケアホールディングス株式会社","holder_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","holder_sec_code":"3417","doc_id":"S100YF0K","period_end":"2026-03-31","holder_table":"largest","shares":832000,"book_value_yen":9160000000,"prior_shares":832000,"prior_book_value_yen":6450000000,"purpose_ja":"・同社株式は、当社グループの事業活動の円滑化のため保有しております。・同社グループは、当社グループにおける主要な仕入先であり、当社の事業継続に不可欠な取引先であります。・当社グループは保有株式について、配当・取引額に加え、経営戦略上の重要性や事業上の関係等を総合的に判断し、保有の便益とリスクの見合いを勘案し保有しております。定量的な保有効果については、取引先との関係性を考慮し記載しませんが、上記方針に基づいて総合的に保有効果を判断しております。","reciprocal":"無(注１)","pct_outstanding":0.1575365473855156,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":26.810279224960485,"pct_of_holder_assets":6.172797908257128,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":34166000000,"holder_total_assets_yen":148393000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社マツキヨココカラ＆カンパニー","holder_name_en":"MatsukiyoCocokara&Co.","holder_sec_code":"3088","doc_id":"S100YD1I","period_end":"2026-03-31","holder_table":"reporting","shares":500000,"book_value_yen":5505000000,"prior_shares":500000,"prior_book_value_yen":3876000000,"purpose_ja":"（保有目的）商品の安定供給（商品仕入）を通じた当社事業の円滑化のため保有（定量的な保有効果）（注）２","reciprocal":"無","pct_outstanding":0.09467340588071851,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":1.0111102743864921,"pct_of_holder_assets":0.7283374193437422,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":544451000000,"holder_total_assets_yen":755831000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":469100,"book_value_yen":5165000000,"prior_shares":469100,"prior_book_value_yen":3637000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.08882258939729011,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.6071277859995039,"pct_of_holder_assets":0.46678083894027644,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ＳＯＭＰＯホールディングス株式会社","holder_name_en":"Sompo Holdings, Inc.","holder_sec_code":"8630","doc_id":"S100YC6Z","period_end":"2026-03-31","holder_table":"largest","shares":400000,"book_value_yen":4404000000,"prior_shares":400000,"prior_book_value_yen":3101000000,"purpose_ja":"上記①イ.保有目的Ａ","reciprocal":"無","pct_outstanding":0.07573872470457481,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.08521963697286072,"pct_of_holder_assets":0.023672705177420584,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":5167823000000,"holder_total_assets_yen":18603704000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"野村ホールディングス株式会社","holder_name_en":"Nomura Holdings, Inc.","holder_sec_code":"8604","doc_id":"S100YC5C","period_end":"2026-03-31","holder_table":"reporting","shares":300000,"book_value_yen":3303000000,"prior_shares":300000,"prior_book_value_yen":2326000000,"purpose_ja":"ホールセール部門を中心とした、ビジネス機会創出、取引関係の維持・強化・拡大のため","reciprocal":"無","pct_outstanding":0.0568040435284311,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.08568282309726674,"pct_of_holder_assets":0.005272489790836356,"holder_equity_basis":"usgaap_consolidated","holder_equity_yen":3854915000000,"holder_total_assets_yen":62645925000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"松竹株式会社","holder_name_en":"Shochiku Co., Ltd.","holder_sec_code":"9601","doc_id":"S100Y66K","period_end":"2026-02-28","holder_table":"reporting","shares":223000,"book_value_yen":2388000000,"prior_shares":223000,"prior_book_value_yen":1633000000,"purpose_ja":"当企業グループの演劇・映像関連事業における主要関係先として、関係維持・強化のために保有しております。保有意義、取引関係、配当、株価、資本コスト等を踏まえ総合的に勘案し、保有の合理性を検討しております。定量的な保有効果については、取引先との秘密保持の観点から記載しておりません。","reciprocal":"有","pct_outstanding":0.042224339022800456,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":2.2047011466661743,"pct_of_holder_assets":1.0410626860986743,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108314000000,"holder_total_assets_yen":229381000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"栗田工業株式会社","holder_name_en":"Kurita Water Industries Ltd.","holder_sec_code":"6370","doc_id":"S100YBAT","period_end":"2026-03-31","holder_table":"reporting","shares":200000,"book_value_yen":2202000000,"prior_shares":200000,"prior_book_value_yen":1550000000,"purpose_ja":"水処理装置のメンテナンス等の取引を行っており、同社グループ各社との良好な関係の維持・強化のために中長期的に保有しております。","reciprocal":"有","pct_outstanding":0.037869362352287404,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.645461980178865,"pct_of_holder_assets":0.3901336234236086,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":341151000000,"holder_total_assets_yen":564422000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ほくやく・竹山ホールディングス","holder_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","holder_sec_code":"3055","doc_id":"S100YJPG","period_end":"2026-03-31","holder_table":"largest","shares":170600,"book_value_yen":1878000000,"prior_shares":170600,"prior_book_value_yen":1322000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため（定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.03230256608650116,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":2.9042883874858885,"pct_of_holder_assets":1.2062819154061084,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ブリヂストン","holder_name_en":"BRIDGESTONE CORPORATION","holder_sec_code":"5108","doc_id":"S100XRPR","period_end":"2025-12-31","holder_table":"reporting","shares":200000,"book_value_yen":1775000000,"prior_shares":200000,"prior_book_value_yen":1720000000,"purpose_ja":"ソリューション事業における取引・協業関係の維持・強化","reciprocal":"無","pct_outstanding":0.037869362352287404,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.04847352103190978,"pct_of_holder_assets":0.030881891120020946,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3661793000000,"holder_total_assets_yen":5747705000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アステナホールディングス株式会社","holder_name_en":"Astena Holdings Co., Ltd.","holder_sec_code":"8095","doc_id":"S100XN2T","period_end":"2025-11-30","holder_table":"reporting","shares":15960,"book_value_yen":141000000,"prior_shares":15960,"prior_book_value_yen":138000000,"purpose_ja":"定量的な保有効果の記載は困難ですが、主にファインケミカル事業における取引先であり、良好な関係の維持、強化を図るために保有しております。信頼関係の構築・維持強化の必要性や事業上の取引状況等に基づく保有意義、同社との取引関係等による経済合理性について経営陣が定期的に検証・審議を行い、保有の合理性があると判断しております。","reciprocal":"無","pct_outstanding":0.0030219751157125347,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.5146548892214476,"pct_of_holder_assets":0.18690102199069472,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":27397000000,"holder_total_assets_yen":75441000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"小林製薬株式会社","holder_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4967","doc_id":"S100XSXS","period_end":"2025-12-31","holder_table":"reporting","shares":100,"book_value_yen":0,"prior_shares":100,"prior_book_value_yen":0,"purpose_ja":"株主総会出席のために保有しております。","reciprocal":"無","pct_outstanding":1.89346811761437e-05,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":211008000000,"holder_total_assets_yen":275329000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社カーリット","holder_name_en":"Carlit Co., Ltd.","holder_sec_code":"4275","doc_id":"S100YIGR","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":64000,"prior_book_value_yen":496000000,"purpose_ja":"主に化学品事業部門の製品の販売、原材料の購入等円滑な取引を行うために保有しておりましたが、当社の政策保有株式の保有方針に基づき株式を売却いたしました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":39793000000,"holder_total_assets_yen":57674000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":800000,"prior_book_value_yen":6202000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"無(注)３","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ＴＢＳホールディングス","holder_name_en":"TBS HOLDINGS, INC.","holder_sec_code":"9401","doc_id":"S100YI1U","period_end":"2026-03-31","holder_table":"second_largest","shares":null,"book_value_yen":null,"prior_shares":666000,"prior_book_value_yen":5163000000,"purpose_ja":"保有意義の妥当性を検討した結果、売却が妥当であると判断し、当事業年度において全株式を売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1135390000000,"holder_total_assets_yen":1628220000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"largest","note_no":"1","text_ja":"（注）１．定量的な保有効果については、秘密保持の観点から記載を控えております。"},{"holder_table":"largest","note_no":"2","text_ja":"２．当社の株式保有の有無は、大塚ホールディングス㈱株式に係る直接保有のみを記載しております。"},{"holder_table":"reporting","note_no":"1","text_ja":"（注）１．定量的な保有効果については、秘密保持の観点から記載を控えております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２．当社の株式保有の有無は、大塚ホールディングス㈱株式に係る直接保有のみを記載しております。"},{"holder_table":"second_largest","note_no":"1","text_ja":"（注）１．定量的な保有効果については、秘密保持の観点から記載を控えております。"},{"holder_table":"second_largest","note_no":"2","text_ja":"２．当社の株式保有の有無は、大塚ホールディングス(株)株式に係る直接保有のみを記載しております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"largest","share_class":"listed","issues_increased":8,"acquisition_cost_yen":20000000,"issues_decreased":16,"sale_proceeds_yen":936000000,"entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","issues_increased":1,"acquisition_cost_yen":99000000,"issues_decreased":2,"sale_proceeds_yen":14000000,"entity_scope":"largest_holding_company","share_scope":"unlisted"},{"holder_table":"reporting","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"},{"holder_table":"second_largest","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":1,"sale_proceeds_yen":297000000,"entity_scope":"second_largest_holding_company","share_scope":"listed"},{"holder_table":"second_largest","share_class":"unlisted","issues_increased":7,"acquisition_cost_yen":5127000000,"issues_decreased":4,"sale_proceeds_yen":19078000000,"entity_scope":"second_largest_holding_company","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":94236000000,"listed_yen":54938000000,"unlisted_yen":39298000000,"listed_issues":36,"unlisted_issues":40,"equity_yen":3033444000000,"equity_basis":"ifrs_consolidated_excl_nci","total_assets_yen":4197562000000,"assets_basis":"ifrs_consolidated","pct_of_equity":3.1065679801572075,"pct_of_assets":2.2450174648998633,"equity_basis_label":"Consolidated equity attributable to owners of the parent (IFRS)","assets_basis_label":"Consolidated total equity (IFRS)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":5776000000,"issue_count":3,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":7240000000,"issue_count":2,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"},{"holder_table":"largest","share_class":"listed","book_value_yen":46702000000,"issue_count":30,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"listed"},{"holder_table":"largest","share_class":"unlisted","book_value_yen":1897000000,"issue_count":20,"holder_table_label":"Largest holder in the group","entity_scope":"largest_holding_company","share_scope":"unlisted"},{"holder_table":"second_largest","share_class":"listed","book_value_yen":2460000000,"issue_count":3,"holder_table_label":"Second largest holder in the group","entity_scope":"second_largest_holding_company","share_scope":"listed"},{"holder_table":"second_largest","share_class":"unlisted","book_value_yen":30161000000,"issue_count":18,"holder_table_label":"Second largest holder in the group","entity_scope":"second_largest_holding_company","share_scope":"unlisted"}],"scale_history":[{"year":"2021","period_end":"2021-12-31","policy_total_yen":100456000000,"equity_yen":2010994000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":4.99534061265225,"pct_of_assets":3.561114035694092},{"year":"2022","period_end":"2022-12-31","policy_total_yen":97103000000,"equity_yen":2225407000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":4.3633816196318245,"pct_of_assets":3.1296128939935204},{"year":"2023","period_end":"2023-12-31","policy_total_yen":101104000000,"equity_yen":2393683000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":4.22378401818453,"pct_of_assets":3.007933967304962},{"year":"2024","period_end":"2024-12-31","policy_total_yen":103283000000,"equity_yen":2733580000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.778305372441999,"pct_of_assets":2.762130704785531},{"year":"2025","period_end":"2025-12-31","policy_total_yen":94236000000,"equity_yen":3033444000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":3.1065679801572075,"pct_of_assets":2.2450174648998633}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2021","period_end":"2021-12-31","named_holdings":70,"book_value_yen":77079000000},{"year":"2022","period_end":"2022-12-31","named_holdings":74,"book_value_yen":59162000000},{"year":"2023","period_end":"2023-12-31","named_holdings":75,"book_value_yen":58001000000},{"year":"2024","period_end":"2024-12-31","named_holdings":65,"book_value_yen":56896000000},{"year":"2025","period_end":"2025-12-31","named_holdings":50,"book_value_yen":54921000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}